Vaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

MicroStrategy’s Andrew Kang talks about bitcoin holdings, Krispy Kreme’s Jeremiah Ashukian discusses business model changes ...